Holy Moly - this is an impressive result.
IMU's team are certainly not sitting on their hands.
Conclusions drawn from the study include;
• HER-Vaxx treatment produced robust anti-HER-2-IgG* and IgG1 antibody
responses (p<0.001).
• HER-Vaxx-based vaccination of patients with HER-2 overexpressing
gastric/gastro-esophageal junction cancer (GC) induced anti-HER-2-IgG and IgG1
subclass antibody responses (p<0.001).
• HER-Vaxx induced antibodies correlated with tumour reduction (p=0.001)
• Compared to chemotherapy alone, the vaccination resulted in a statistically
significant overall survival benefit.
• The present data further validate the proof of concept for a first-in-class B-cell
immunotherapy based on HER-2/neu peptides.
- Forums
- ASX - By Stock
- IMU
- Ann: HER-Vaxx induced antibodies correlated with tumour reduction
Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-18
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
7.8¢ |
Change
0.016(25.8%) |
Mkt cap ! $587.9M |
Open | High | Low | Value | Volume |
7.3¢ | 8.0¢ | 7.3¢ | $5.452M | 71.40M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 1191273 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 2079208 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 2089104 | 0.079 |
17 | 2033360 | 0.078 |
8 | 808108 | 0.077 |
12 | 685236 | 0.076 |
7 | 892034 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 4333236 | 33 |
0.081 | 4064528 | 14 |
0.082 | 1549649 | 11 |
0.083 | 919987 | 9 |
0.084 | 1131916 | 5 |
Last trade - 10.54am 02/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online